Navigation Links
MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development
Date:1/23/2009

SCOTTSDALE, Ariz., Jan. 23 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published two new reports providing critical strategic insight for companies developing therapies to treat hematologic malignancies. These reports are based on primary interviews conducted with hematology experts from North America immediately following the American Society of Hematology (ASH) annual meeting.

The first report, entitled "Thought Leader Insight & Analysis - AML/MDS," focuses on acute myelogenous leukemia and myelodysplastic syndrome. "This report highlights the most important data presented at ASH, and clarifies the ways these data will change clinical practice," according to Jeff Berk, MedPredict president. "A key emphasis of this report is transplant, and how pharmaceuticals and biologicals better prepare patients for transplant. Our thought leader panel discusses how to achieve complete responses, how they are thinking about combination therapy, and new ways for attacking quiescent malignant stem cells."

The second report, entitled "Thought Leader Insight & Analysis - Multiple Myeloma/Lymphoma," focuses on how the clinical data presented at ASH is likely to translate into changing treatment paradigms. "This report brings together the diverse perspectives of experts who grapple with a wide spectrum of issues related to these hematologic malignancies, including clinical pathology, community based patients, tertiary care treatment, and medical oncology from the strategic vantage point of clinical commercial development," said Berk.

Topics this report addresses include:

    -- Reimbursement: oral vs. parenteral; induction vs. maintenance.

    -- Multiple myeloma/lymphoma treatment strategies, including:

         - transplant eligible/non-transplant eligible;
         - induction/maintenance;
         - doublets/triplets;
         - community/tertiary care;
         - +65 years old/younger; and
         - approval pathways.

Companies mentioned in these reports include: Allos, Amgen, Bayer-Schering, Biogen Idec, BMS (Kosan), Celgene, Cell Therapeutics, Cephalon, Eisai, Genentech, Genmab, Genzyme, Geron, GSK, Gloucester, ImmunoGen, Incyte, Keryx, Mayo Scottsdale, Merck, Nereus, Novartis, PDL Biopharma, Proteolix, Rigel, Roche, Seattle Genetics, Takeda/Millennium, Vion, Wyeth, Xencor.

This report can be purchased by contacting MedPredict (www.medpredict.com).

About MedPredict

MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiovascular Meds May Be Beneficial in Alzheimers Disease, According to MedPredict Report
2. Media Alert: PricewaterhouseCoopers Publishes Brief on the Impact of Government Health Reform on U.S. Employers
3. Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008
4. Zebrafish Journal Publishes Skin Pigmentation Studies That Shed Light on the Evolution of Race
5. HealthInsuranceFinders.com Publishes Health Insurance Guide for the Recently Unemployed
6. Dynamics Group AG Publishes Research Report on Senetek
7. PharmacyChecker.com Publishes Safe Strategies for Drug Savings to Help All Americans Get Affordable Medication
8. AMA Journal Publishes Study Showing Evidence of a Major Environmental Trigger For Autism
9. (Report) World Privacy Forum Publishes Red Flag Rule Suggestions for Hospitals and Providers; New FTC-Enforced Rules Go Into Effect Nov. 1, Can Apply to Health Care Providers
10. Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improved Cardiac Relaxation in Study of Patients With Long QT Syndrome
11. The Scientific Business of Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology: